April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Patient Perspectives of Anti-VEGF Intravitreal Injections
Author Affiliations & Notes
  • Morgan Fallor
    Northwestern University Department of Ophthalmology, Chicago, IL
  • Rukhsana Mirza
    Northwestern University Department of Ophthalmology, Chicago, IL
  • Alice T Lyon
    Northwestern University Department of Ophthalmology, Chicago, IL
  • Anupam Jayaram
    Northwestern University Department of Ophthalmology, Chicago, IL
  • Manjot Gill
    Northwestern University Department of Ophthalmology, Chicago, IL
  • Footnotes
    Commercial Relationships Morgan Fallor, None; Rukhsana Mirza, None; Alice Lyon, None; Anupam Jayaram, None; Manjot Gill, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 172. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Morgan Fallor, Rukhsana Mirza, Alice T Lyon, Anupam Jayaram, Manjot Gill; Patient Perspectives of Anti-VEGF Intravitreal Injections. Invest. Ophthalmol. Vis. Sci. 2014;55(13):172.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To gain insight into patients’ perspectives of intravitreal injection treatments in regards to their understanding of their disease, views on their clinical course, and overall experience with management.


An IRB-approved prospective 28 question survey was created by 3 retina specialists (RM, MG, AL) and administered to patients undergoing intravitreal injection therapy at Northwestern Medical Faculty Foundation outpatient retina clinic between June and July 2013. All patients were consented by the same investigator (MF) and completed the survey on their own or with assistance of the investigator. The survey questions were designed to qualitatively assess: patients’ understanding of their diagnosis, factors considered when choosing their treatment, anxiety level regarding treatment, treatment experience, and overall outcomes. In addition, a chart review was performed on each patient to obtain demographic data (age, gender, and insurance status) as well as clinical information including diagnosis, duration of diagnosis, vision at presentation, vision at time of survey, drug used for injection, number of injections received, and frequency of injections.


There were a total of 107 patients surveyed (65 women and 43 men, age 30-96 years). The most common indication for injections in this study was exudative age related macular degeneration. There was objective improvement (increase in 1 line) in best corrected vision in 67% of all patients. Patients’ perceptions of whether their treatment improved their vision were as follows: 48% noted improvement, 32% did not, and 15% were unsure. Of those who experienced anxiety prior to their first injection, 68% have less anxiety since being treated. In regard to deciding which treatment to choose, 77% of patients rely more on their doctor’s choice, than FDA approval, clinical trials, cost, and interval between injections. Finally, 73% patients surveyed reported that they would be willing to undergo intravitreal injections indefinitely, stating that they understood that receiving injections was better than the alternative.


Despite preconceived notions about intravitreal injections, almost half (48%) of patients subjectively felt that the treatment is improving their vision, and the majority of patients (67%) objectively demonstrated this improvement of acuity. Additionally, most patients surveyed reported their willingness to continue on with intravitreal injections.

Keywords: 609 neovascularization • 688 retina  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.